title: Perchlorate clinical pharmacology and human health: a review.
abstract: Potassium perchlorate has been used at various times during the last 50 years to treat hyperthyroidism. Since World War II ammonium perchlorate has been used as a propellant for rockets. In 1997, the assay sensitivity for perchlorate in water was improved from 0.4 mg/L (ppm) to 4 microg/L (ppb). As a result, public water supplies in Southern California were found to contain perchlorate ions in the range of 5 to 8 ppb, and those in Southern Nevada were found to contain 5 to 24 ppb. Research programs have been developed to assess the safety or risk from these exposures and to assist state and regulatory agencies in setting a reasonable safe level for perchlorate in drinking water. This report reviews the evidence on the human health effects of perchlorate exposure. Perchlorate is a competitive inhibitor of iodine uptake. All of its pharmacologic effects at current therapeutic levels or lower are associated with inhibition of the sodium-iodide symporter (NIS) on the thyroid follicular cell membrane. A review of the medical and occupational studies has been undertaken to identify perchlorate exposure levels at which thyroid hormone levels may be reduced or thyrotropin levels increased. This exposure level may begin in the 35 to 100 mg/d range. Volunteer studies have been designed to determine the exposure levels at which perchlorate begins to affect iodine uptake in humans. Such effects may begin at levels of approximately 1 mg/d. Environmental studies have assessed the thyroidal health of newborns and adults at current environmental exposures to perchlorate and have concluded that the present levels appear to be safe. Whereas additional studies are underway both in laboratory animals and in the field, it appears that a safe level can be established for perchlorate in water and that regulatory agencies and others are now trying to determine that level.
authors.affiliation: Consultants in Epidemiology and Occupational Health, Washington, D.C. 20007, USA. offie@CEOH.com
authors.forename: O P
authors.initials: OP
authors.lastname: Soldin
authors.forename: L E
authors.initials: LE
authors.lastname: Braverman
authors.forename: S H
authors.initials: SH
authors.lastname: Lamm
mesh_terms: D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D006262:Health; D006801:Humans; D007455:Iodine / Q000378:metabolism; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D010472:Perchlorates / Q000009:adverse effects / Q000494:pharmacology*; D027981:Symporters; D013961:Thyroid Gland / Q000187:drug effects / Q000378:metabolism; D014874:Water Pollutants, Chemical / Q000009:adverse effects / Q000494:pharmacology; D000099209:Sodium-Iodide Symporters
chemical_list: D002352:Carrier Proteins; D007455:Iodine; D008565:Membrane Proteins; D010472:Perchlorates; D027981:Symporters; D014874:Water Pollutants, Chemical; D000099209:Sodium-Iodide Symporters